{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:35:24Z","timestamp":1790573724196,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorder (PCSM-TLPD) is a rare subtype of indolent lymphoproliferative disease. The treatment, investigations and follow-up protocol are being re-evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To use our service evaluation to understand the presentation, response rate, relapse rate, treatment variation, progression-free (PFS) and overall survival (OS) of our cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified 86 patients with PCSM-TLPD from our skin tumour unit database who were diagnosed by the specialist multidisciplinary team at our centre between 2005 and 2024. As well as demographics and clinical features, OS, PFS, response to treatment and risk factors for relapse were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-six patients [mean (SD) age 54.9 (14.1) years; median 56\u2005years (range 17\u201387)] were included. The majority of PCSM-TLPD lesions presented as solitary nodules (n = 75) on the head and neck (n = 51). Eighty-one patients underwent imaging (positron emission tomography, n = 44; computed tomography of the thorax, abdomen and pelvis, n = 37), with no evidence of nodal or systemic involvement in 100% of cases. Forty-seven patients had a diagnostic biopsy that resulted in spontaneous resolution for 16 patients. Thirty-one patients had a residual lesion and were treated with topical steroids (n = 20) or radiotherapy (n = 11). Thirty-nine patients had a complete excision, followed by monitoring alone for 33 patients. Six had radiotherapy after excision. All patients achieved complete remission. Patients initially presenting with multiple lesions (n = 11) were more likely to relapse [7 of 11 with multiple (64%) vs. 3 of 75 (4%) with solitary lesions] (P &amp;lt; 0.001). Three patients died from unrelated illnesses during follow-up. The median duration of follow-up was 3.1\u2005years (interquartile range 1.2\u20134.9). The median PFS was not reached due to insufficient events. The overall relapse rate was 12% following initial monitoring or treatment. To date, disease-specific survival is 100%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PCSM-TLPD carries an excellent prognosis, especially for those presenting with a solitary lesion. There was no disease-related death in our patients up to 20\u2005years after presentation. Staging scans confirm no systemic disease and may no longer be required for these patients. Patients can be monitored or treated with low dose radiotherapy (8\u2005Gy in two fractions) if they do not respond to topical steroids.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf338","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:51:14Z","timestamp":1756813874000},"page":"1214-1220","source":"Crossref","is-referenced-by-count":1,"title":["Primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorder: 20\u2005years of experience from\u00a0a specialist centre"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4381-3297","authenticated-orcid":false,"given":"Sophie E L","family":"Bashall","sequence":"first","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1815-3502","authenticated-orcid":false,"given":"Bjorn R","family":"Thomas","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7116-906X","authenticated-orcid":false,"given":"Van","family":"Sim","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0880-2792","authenticated-orcid":false,"given":"Mary","family":"Wain","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Child","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Whittaker","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Morris","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"2025111813172140200_ljaf338-B1","first-page":"553","article-title":"Cutaneous peripheral T-cell lymphomas, unspecified\/NOS and rare subtypes: a heterogeneous group of challenging cutaneous lymphomas","volume":"147","author":"Kempf","year":"2012","journal-title":"G Ital Dermatol Venereol"},{"key":"2025111813172140200_ljaf338-B2","author":"Willemze"},{"key":"2025111813172140200_ljaf338-B3","doi-asserted-by":"crossref","first-page":"104126","DOI":"10.1016\/j.lpm.2022.104126","article-title":"Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification","volume":"51","author":"Willemze","year":"2022","journal-title":"Presse Med"},{"key":"2025111813172140200_ljaf338-B4","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"2025111813172140200_ljaf338-B5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/DAD.0b013e31819f19bb","article-title":"Primary cutaneous CD4+ small-\/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases","volume":"31","author":"Beltraminelli","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"2025111813172140200_ljaf338-B6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1159\/000511473","article-title":"The clinical spectrum of primary cutaneous CD4+ small\/medium-sized pleomorphic T-cell lymphoproliferative disorder: an updated systematic literature review and case series","volume":"237","author":"Surmanowicz","year":"2021","journal-title":"Dermatology"},{"key":"2025111813172140200_ljaf338-B7","first-page":"123","article-title":"Primary cutaneous CD4+ small\/medium pleomorphic T-cell lymphoproliferative disorder: Where do we stand? A systematic review","volume":"17","author":"Salah","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025111813172140200_ljaf338-B8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5045\/br.2017.52.4.326","article-title":"Differential diagnosis of primary cutaneous CD4+ small\/medium T-cell lymphoproliferative lesions: a report of three cases","volume":"52","author":"Kim","year":"2017","journal-title":"Blood Res"},{"key":"2025111813172140200_ljaf338-B9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/cup.12806","article-title":"Clinicopathological and molecular study of primary cutaneous CD4+ small\/medium-sized pleomorphic T-cell lymphoma","volume":"43","author":"Alberti-Violetti","year":"2016","journal-title":"J Cutan Pathol"},{"key":"2025111813172140200_ljaf338-B10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/path.1711720110","article-title":"Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma","volume":"172","author":"Beljaards","year":"1994","journal-title":"J Pathol"},{"key":"2025111813172140200_ljaf338-B11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/PAS.0b013e318230df87","article-title":"Expression of programmed death-1 in primary cutaneous CD4-positive small\/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma","volume":"36","author":"\u00c7etin\u00f6zman","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"2025111813172140200_ljaf338-B12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jclinpath-2017-204761","article-title":"T cell clonality assessment: past, present and future","volume":"71","author":"Mahe","year":"2018","journal-title":"J Clin Pathol"},{"key":"2025111813172140200_ljaf338-B13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2133.2008.08670.x","article-title":"Pseudoclonality in cutaneous pseudolymphomas: a pitfall in interpretation of rearrangement studies","volume":"159","author":"Ber","year":"2008","journal-title":"Br J Dermatol"},{"key":"2025111813172140200_ljaf338-B14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/cup.14694","article-title":"Assessing T-cell receptor clonality by next-generation sequencing in atypical cutaneous lymphoid infiltrates and cutaneous T-cell lymphoma: a scoping review","volume":"51","author":"Shinohara","year":"2024","journal-title":"J Cutan Pathol"},{"key":"2025111813172140200_ljaf338-B15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/cup.14143","article-title":"Next-generation sequencing confirms T-cell clonality in a subset of pediatric pityriasis lichenoides","volume":"49","author":"Raghavan","year":"2022","journal-title":"J Cutan Pathol"},{"key":"2025111813172140200_ljaf338-B16","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/PAS.0000000000001470","article-title":"Primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorders a clinical, pathologic, and molecular study of 60 cases presenting with a single lesion: a multicenter study of the French Cutaneous Lymphoma Study Group","volume":"44","author":"Beltzung","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"2025111813172140200_ljaf338-B17","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jaad.2021.04.067","article-title":"Primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorder: diagnosis and management","volume":"86","author":"Besch-Stokes","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025111813172140200_ljaf338-B18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ad.2015.02.015","article-title":"P rimary cutaneous CD4+ small\/medium-sized T-cell lymphoma with spontaneous regression after biopsy","volume":"106","author":"Gonz\u00e1lez Fern\u00e1ndez","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"2025111813172140200_ljaf338-B19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1365-2133.2007.07751.x","article-title":"Primary cutaneous peripheral T-cell lymphoma, unspecified, that completely regressed after skin biopsy","volume":"156","author":"Madan","year":"2007","journal-title":"Br J Dermatol"},{"key":"2025111813172140200_ljaf338-B20","doi-asserted-by":"crossref","first-page":"109430","DOI":"10.1016\/j.radonc.2022.11.019","article-title":"Excellent treatment outcomes from low dose radiation therapy for primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorder","volume":"178","author":"Ward","year":"2023","journal-title":"Radiother Oncol"},{"key":"2025111813172140200_ljaf338-B21","first-page":"437","article-title":"Radiation therapy-associated toxicity: etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025111813172140200_ljaf338-B22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clon.2015.01.009","article-title":"Radiotherapy for benign disease: current evidence, benefits and risks","volume":"27","author":"Taylor","year":"2015","journal-title":"Clin Oncol"},{"key":"2025111813172140200_ljaf338-B23"},{"key":"2025111813172140200_ljaf338-B24","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1200\/JCO.2008.16.1307","article-title":"Primary cutaneous small\/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome","volume":"26","author":"Garcia-Herrera","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025111813172140200_ljaf338-B25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/cup.14609","article-title":"Cutaneous lymphoproliferative disorders: back to the future","volume":"51","author":"Willemze","year":"2024","journal-title":"J Cutan Pathol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf338\/64222664\/ljaf338.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1214\/64222664\/ljaf338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1214\/64222664\/ljaf338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T18:17:32Z","timestamp":1763489852000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/6\/1214\/8249318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,8]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf338","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,8]]}}}